Verition Fund Management
HARP

Verition Fund Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Verition Fund Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,479
Closed -$3.66M – 2236
2021
Q1 		$3.66M Buy
+17,479
New +$3.5M 0.04% 261
2020
Q4 		– Sell
-2,250
Closed -$382K – 1455
2020
Q3 		$382K Buy
+2,250
New +$325K 0.01% 695

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Verition Fund Management's HARP Position: Q2 2021 in Review

Verition Fund Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2021, closing a stake of 17,479 shares — an estimated $3.66M sold.

Verition Fund Management first reported a position in HARP in Q3 2020 and held it in 2 quarters. The position peaked at $3.66M in Q1 2021. 85 funds tracked by Wall St. Rank hold HARP as of Q2 2021.

  • Verition Fund Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Verition Fund Management sold 17,479 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $3.66M.
  • Verition Fund Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Verition Fund Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.66M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Verition Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.